Keep Me Logged In
I think a lot of it had to do with pricing concerns over Gilead's Sovaldi, says Jason Kolbert, Maxim Group, sharing his thoughts on the future of the biotech sector and pending IPOs.
Got a confidential news tip? We want to hear from you.
Sign up for free newsletters and get more CNBC delivered to your inbox
© 2018 CNBC LLC. All Rights Reserved. A Division of NBCUniversal
Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Data also provided by